Center-Authored Papers

Filters: Author is Rizvi, Naiyer A  [Clear All Filters]
G
Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW et al..  2016.  Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(25):2980-7. Abstract
H
Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA et al..  2016.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.. The Lancet. Oncology. Abstract
L
Leighl NB, Rizvi NA, de Lima LG, Arpornwirat W, Rudin CM, Chiappori AA, Ahn M-J, Chow LQM, Bazhenova L, Dechaphunkul A et al..  2016.  Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.. Clinical lung cancer. Abstract
P
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E et al..  2017.  Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016719476. Abstract
R
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW et al..  2016.  Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract